Wegovy and Heart Health: What the Trial Evidence Actually Shows

The SELECT trial: where the heart-health evidence comes from

The cardiovascular case for Wegovy rests almost entirely on a single, large, rigorous trial. SELECT enrolled 17,604 adults across 41 countries who had established cardiovascular disease and a BMI of 27 or above but did not have type 2 diabetes. Participants received either semaglutide 2.4mg or a placebo over a median of roughly five years. The primary outcome was a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke.

Semaglutide reduced that combined outcome by around 20%. That figure held up across most subgroups the researchers examined, including people who lost relatively little weight. The implication is significant: the benefit does not appear to be purely a downstream effect of a smaller body. Reduced inflammation, improvements in blood pressure and lipid profiles, and direct effects on the cardiovascular system are all proposed mechanisms, though the precise pathways are still being studied.

The MHRA granted Wegovy a separate UK authorisation covering this cardiovascular indication following a review of the SELECT data, which is why semaglutide's cardiovascular properties are discussed distinctly from its weight-management licence. This is an unusual step; few weight-management medicines have ever earned cardiovascular outcome data at this scale.

What the cardiovascular licence does and does not cover

The UK authorisation for Wegovy's cardiovascular indication applies to adults who already have established cardiovascular disease and a BMI of at least 27. It is not a licence for primary prevention (people who have risk factors but no diagnosed heart condition), and it is not a justification for using Wegovy purely to protect the heart in someone who does not otherwise meet prescribing criteria.

Understanding what those heart-health benefits actually mean for individual patients requires reading the trial carefully. SELECT participants were already on standard cardiovascular therapies (statins, antiplatelets and so on); Wegovy was added on top. The trial does not tell us what Wegovy would do as the only intervention, or in someone without pre-existing disease.

The MHRA also approved a separate indication for Wegovy in MASH, a form of fatty liver disease associated with metabolic risk, in July 2026. These expanding indications reflect a widening picture of what semaglutide may do beyond weight loss, though each is governed by its own prescribing criteria. For anyone curious about how Wegovy interacts with the heart more broadly, that fuller picture is worth understanding before a consultation.

For a more detailed look at the specific mechanisms and what the evidence suggests day to day, our page on how Wegovy helps heart health goes deeper into the biology and what the trial data shows in practical terms.

Safety considerations that matter for people with heart conditions

If you have pre-existing cardiovascular disease, a few side-effect patterns are worth knowing before you speak to a prescriber. The most common effects are gastrointestinal: nausea, constipation, diarrhoea and reflux are frequently reported, particularly in the early weeks of titration. These are generally mild to moderate and tend to settle as the body adjusts, but dehydration from significant nausea or vomiting can be a concern for anyone on antihypertensives or diuretics.

Wegovy is also associated with a modest increase in heart rate in some people. The clinical significance of that for cardiovascular patients is something a prescriber will weigh against the broader benefit; our page on Wegovy and heart rate covers what is known in more detail. The SELECT trial did not find that heart-rate changes offset the cardiovascular benefit at the population level, but individual circumstances vary.

The MHRA monitors Wegovy under a Black Triangle designation, meaning additional surveillance is ongoing. Patients can report suspected side effects via the Yellow Card scheme. The NHS medicines page for semaglutide sets out the full side-effect profile clearly and is worth reading alongside your Patient Information Leaflet.

Private access and what to realistically expect

On the NHS, Wegovy is available through specialist weight management services under NICE guidance, and waiting lists can be long. For people who want to explore access now, a regulated private pharmacy is the alternative route, subject to clinical suitability. If you're thinking about how Wegovy is priced privately, that page sets out what to look for in an inclusive quote and what the market looks like since Lilly's 2025 price changes.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation. Once approved, your treatment is dispatched the same day if you order before midday, and arrives via DPD the next working day in plain, unbranded packaging. There is no way to tell from the box what is inside. If you are on multiple cardiovascular medicines or have a complex history, the prescriber will consider that in the round; this is exactly the kind of context that makes individual clinical review important rather than optional.

Wegovy prescribed for heart-health reasons in a private setting still requires that review. The weight-loss treatment overview explains what the consultation covers, and our Wegovy page outlines the full prescribing pathway. When you're ready to speak with a clinician, our prescribers are available seven days a week for aftercare as well as initial assessment.